Adrian Hobson, FRSC, is a Senior Research Fellow at Abbvie, and an adjunct Professor of Chemistry at Clark University in Worcester, MA, USA. With 30 years of experience as a medicinal chemist, he started his journey at Boots Pharmaceuticals, Nottingham UK, where he worked on anti-depressants and anti-psychotics, and in the Special Synthesis group making metabolites and possible impurities. After the company was acquired by BASF in 1994, he formed the High Speed Analoging team, working there for 6 years until he transferred to the BASF Bioresearch Corporation at Worcester, MA, USA, where he formed a new High Speed Analoging team to support both oncology and immunology. He spent the next 12 years working in medicinal chemistry on kinase, GPCR and NHR targets including selective glucocorticoid receptor modulators. When AbbVie split from Abbott, Dr Hobson switched his attention to immunology antibody-drug conjugates, where he has pioneered the use of glucocorticoid receptor modulators (GRM) as a payload for antibody-drug conjugates.